This monumental scientific achievement occurred within a context of intense international collaboration, rapid technical ...
Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections ...
Ken Bain passed away on Oct. 10. I first learned this news on LinkedIn from Jim Lang, who did know and was directly mentored by Ken Bain and, like the several dozen folks who offered comments on his ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
WRN inhibitors are attracting increasing attention as a niche but fast-emerging segment within precision oncology, driven by ...
The NBA rookie class is off to an incredible start, but there can only be one Rookie of the Year at season's end. The current ...
Many startups focus on features first. We focused on functionality. Can this system scale? Can it handle peak demand? Can it ...
Research and development expense in fiscal Q3 2025 -- $4.5 million versus $4.9 million in fiscal Q3 2024. Net loss -- $5.9 ...
Next 10 years promises two Dell Medical School hospitals, more specialists advancing care, plus a focus on technology and ...
The animated Google Doodle dives into DNA, the foundation of biology, which carries genetic instructions for all living ...
The letters MSRP stand for manufacturer’s suggested retail price. When a car is brand new, that figure appears on the ...
WRN inhibitors are attracting increasing attention as a niche but fast-emerging segment within precision oncology, driven by their role in targeting DNA repair vulnerabilities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback